高级检索
当前位置: 首页 > 详情页

AKR1B10 is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 610041, Chengdu, China
出处:
ISSN:

摘要:
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare and distinct subtype of renal cancer caused by fumarate hydratase (FH) gene mutations. FH negativity and s-2-succinocysteine (2SC) positivity on immunohistochemistry can be used to screen for FH-deficient RCC, but their sensitivity and specificity are not perfect. The expression of AKR1B10, an aldo-keto reductase that catalyzes cofactor-dependent oxidation‒reduction reactions, in renal cell carcinoma (RCC) is unclear. We compared AKR1B10, 2SC, and FH as diagnostic biomarkers for FH-deficient RCC. We included genetically confirmed FH-deficient RCCs (n = 58), genetically confirmed TFE3 translocation RCCs (TFE3-tRCC) (n = 83), clear cell RCCs (ccRCC) (n = 188), chromophobe RCCs (chRCC) (n = 128), and papillary RCCs (pRCC) (n = 97). AKR1B10, 2SC, and FH were informative diagnostic markers. AKR1B10 had 100% sensitivity and 91.4% specificity for FH-deficient RCC. Non-specificity of AKR1B10 was shown in 26.5% of TFE3-tRCCs and 21.6% of pRCCs. 2SC showed 100% sensitivity and 88.9% specificity. However, 2SC non-specificity was evident in multiple RCCs, including pRCC, TFE3-tRCC, ccRCC, and chRCC. FH was 100% specific, but 84.5% sensitive. AKR1B10 served as a highly sensitive and specific diagnostic biomarker. Our findings suggest the value of combining AKR1B10 and 2SC to screen for FH-deficient RCC. AKR1B10+/2SC+/FH- cases can be diagnosed as FH-deficient RCC. Patients with AKR1B10+/2SC+/FH+ are highly suspicious for FH-deficient RCC and should be referred for FH genetic tests.Copyright © 2023. Published by Elsevier Inc.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 1 区 病理学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 病理学
第一作者:
第一作者机构: [1]Department of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China [2]Laboratory of Pathology, West China Hospital, Sichuan University, 610041, Chengdu, China [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 610041, Chengdu, China [*1]Department of Pathology, West China Hospital, Sichuan University, Chengdu, 610041, China [*2]Department of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号